 |
|
Association of Genetic Variations With Nonfatal Venous Thrombosis in Postmenopausal Women
Nicholas L. Smith, PhD, MPH;
Lucia A. Hindorff, PhD;
Susan R. Heckbert, MD, PhD;
Rozenn N. Lemaitre, PhD, MPH;
Kristin D. Marciante, PhD;
Kenneth Rice, PhD;
Thomas Lumley, PhD;
Joshua C. Bis, MS;
Kerri L. Wiggins, MS, RD;
Frits R. Rosendaal, MD, PhD;
Bruce M. Psaty, MD, PhD
JAMA. 2007;297:489-498.
Context Although the roles of clotting proteins and enzymes that activate or inhibit fibrin production and lysis are well characterized, the underlying contribution of genetic variation in these constituents to risk of venous thrombosis (VT) has not been fully investigated.
Objective To describe the association of common genetic variation in 24 coagulation, anticoagulation, fibrinolysis, and antifibrinolysis candidate genes with risk of incident nonfatal VT in postmenopausal women.
Design, Setting, and Participants Population-based case-control study conducted in a large integrated health care system in Washington State. Participants were perimenopausal and postmenopausal women aged 30 to 89 years who sustained a first VT event between January 1995 and December 2002 (n = 349) and 1680 controls matched on age, hypertension status, and calendar year (n = 1680).
Main Outcome Measure Risk of venous thrombosis associated with global variation within a gene as measured by common haplotypes and with individual haplotypes and single nucleotide polymorphisms (SNPs). Significance of the associations was assessed by a .20 threshold of the false-discovery rate q value, which accounts for multiple testing.
Results Only the tissue factor pathway inhibitor gene demonstrated global association with risk (q = .13). Five significant SNP associations were identified across 3 of the candidate genes (factors V, XI, and protein C) in SNP analyses. Two associations have been previously reported. Another 22 variants across 15 genes had P values less than .05 but q values between .20 and .35. Five of these confirm previously reported associations (fibrinogen genes and protein C), 2 were inconsistent with earlier reports (thrombomodulin and plasminogen activator inhibitor 1), and 15 were new discoveries.
Conclusions After accounting for multiple testing, 5 SNPs associated with VT risk were identified, 3 of which have not been previously reported. Replication of these novel associations in other populations is necessary to corroborate these findings and identify which genetic factors may influence VT risk in postmenopausal women.
Author Affiliations: Departments of Epidemiology (Drs Smith, Hindorff, Heckbert, and Psaty and Mr Bis), Medicine (Drs Lemaitre, Marciante, and Psaty and Ms Wiggins), Biostatistics (Drs Rice and Lumley), and Health Services (Dr Psaty), University of Washington, Seattle; and Departments of Clinical Epidemiology and Hematology, Leiden University Medical Center, Leiden, the Netherlands (Dr Rosendaal).
RELATED LETTER
Genetic Association Studies and False Discoveries
Benjamin D. Horne
JAMA. 2007;297(22):2477-2478.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Interpreting Results of Large-Scale Genetic Association Studies: Separating Gold From Fool's Gold
Josée Dupuis and Christopher J. O’Donnell
JAMA. 2007;297(5):529-531.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Gene Variants Associated With Deep Vein Thrombosis
Bezemer et al.
JAMA 2008;299:1306-1314.
ABSTRACT
| FULL TEXT
Gene Discovery in Venous Thrombosis: Progress and Promise
Bovill
JAMA 2008;299:1362-1363.
FULL TEXT
Interleukin-6 Receptor Gene Variations, Plasma Interleukin-6 Levels, and Type 2 Diabetes in U.S. Women
Qi et al.
Diabetes 2007;56:3075-3081.
ABSTRACT
| FULL TEXT
Genetic Association Studies and False Discoveries
Horne
JAMA 2007;297:2477-2478.
FULL TEXT
Interpreting Results of Large-Scale Genetic Association Studies: Separating Gold From Fool's Gold
Dupuis and O'Donnell
JAMA 2007;297:529-531.
FULL TEXT
|
